High share of instrument sales to India and OEM business
Gross profit margin decreased by 3.9 pp
Operating margin increased by 1.5 pp
Investments in new technology platform 20 MSEK
Boule Diagnostics
July 18, 2022
Financials Q2
Net sales, MSEK
Gross margin
141
38%
YoY Growth
EBIT-margin
27%
4%
Cash-flow, MSEK
-8.7
All-time-high revenue for a quarter & stable growth trends past year
Back to pre-pandemic levels last three quarters
Boule grows faster than the market
Boule Diagnostics
July 18, 2022
Sales bridge: Growth for all products
● Strong reported and organic growth in both instruments and consumables
+29%
+29%
+14%
+49%
Boule Diagnostics
July 18, 2022
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Boule Diagnostics AB published this content on 18 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 July 2022 07:43:06 UTC.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
